ArticleBriefings in bioinformatics2021
Virus-CKB: an integrated bioinformatics platform and analysis resource for COVID-19 research.
Article in Briefings in bioinformatics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- nCoVDock2: a docking server to predict the binding modes between COVID-19 targets and its potential ligands.Nucleic acids research · 2023Article
- Bioinformatics-based investigation on the genetic influence between SARS-CoV-2 infections and idiopathic pulmonary fibrosis (IPF) diseases, and drug repurposing.Scientific reports · 2023Article
- Applying the digital data and the bioinformatics tools in SARS-CoV-2 research.Computational and structural biotechnology journal · 2023Review
- The role of machine learning in health policies during the COVID-19 pandemic and in long COVID management.Frontiers in public health · 2023Review
- Identification of host genomic biomarkers from multiple transcriptomics datasets for diagnosis and therapies of SARS-CoV-2 infections.PloS one · 2023Article
- The Spike Mutants Website: A Worldwide Used Resource against SARS-CoV-2.International journal of molecular sciences · 2022Article
- Article
- Elucidation of Binding Features and Dissociation Pathways of Inhibitors and Modulators in SARS-CoV-2 Main Protease by Multiple Molecular Dynamics Simulations.Molecules (Basel, Switzerland) · 2022Article
- D3AI-CoV: a deep learning platform for predicting drug targets and for virtual screening against COVID-19.Briefings in bioinformatics · 2022Article
- COVID19db: a comprehensive database platform to discover potential drugs and targets of COVID-19 at whole transcriptomic scale.Nucleic acids research · 2022Article
- Databases, Knowledgebases, and Software Tools for Virus Informatics.Advances in experimental medicine and biology · 2022Article
- Structures of the SARS-CoV-2 spike glycoprotein and applications for novel drug development.Frontiers in pharmacology · 2022Review
- Drug repositioning: A bibliometric analysis.Frontiers in pharmacology · 2022Review
- Advances in the computational landscape for repurposed drugs against COVID-19.Drug discovery today · 2021Review
- Structure-based drug repurposing against COVID-19 and emerging infectious diseases: methods, resources and discoveries.Briefings in bioinformatics · 2021Article
- IsAb: a computational protocol for antibody design.Briefings in bioinformatics · 2021Article
- Bioinformatics resources facilitate understanding and harnessing clinical research of SARS-CoV-2.Briefings in bioinformatics · 2021Review
- MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs.Briefings in bioinformatics · 2021Article
- Generative chemistry: drug discovery with deep learning generative models.Journal of molecular modeling · 2021Review
- COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics.Nucleic acids research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Given the scale and rapid spread of the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is an urgent need for medicines that can help before vaccines are available. In this study, we present a viral-associated disease-specific chemogenomics knowledgebase (Virus-CKB) and apply our computational systems pharmacology-target mapping to rapidly predict the FDA-approved drugs which can quickly progress into clinical trials to meet the urgent demand of the COVID-19 outbreak. Virus-CKB reuses the underlying platform of our DAKB-GPCRs but adds new features like multiple-compound support, multi-cavity protein support and customizable symbol display. Our one-stop computing platform describes the chemical molecules, genes and proteins involved in viral-associated diseases regulation. To date, Virus-CKB archived 65 antiviral drugs in the market, 107 viral-related targets with 189 available 3D crystal or cryo-EM structures and 2698 chemical agents reported for these target proteins. Moreover, Virus-CKB is implemented with web applications for the prediction of the relevant protein targets and analysis and visualization of the outputs, including HTDocking, TargetHunter, BBB predictor, NGL Viewer, Spider Plot, etc. The Virus-CKB server is accessible at https://www.cbligand.org/g/virus-ckb.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.